What's Happening?
Imbed Biosciences has announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a Healthcare Common Procedure Coding System (HCPCS) Level II code, A2040, to its product Microlyte PainGuard. This synthetic wound matrix incorporates
silver for antimicrobial activity and lidocaine HCl for localized pain management. The new code, effective April 1, 2026, allows healthcare providers to report the product on claims submitted to payers recognizing HCPCS Level II codes. This development is a significant step in establishing billing clarity and supporting claims visibility for the product.
Why It's Important?
The assignment of an HCPCS code to Microlyte PainGuard is crucial for Imbed Biosciences as it facilitates the integration of the product into clinical workflows by providing billing clarity. This move is expected to enhance the product's visibility among healthcare providers and payers, potentially increasing its adoption in wound care settings. The code assignment also underscores the importance of non-opioid pain management solutions in the healthcare industry, aligning with broader efforts to reduce opioid use and improve patient outcomes in wound care.
